Related Experiment Videos
Therapy of blastomycosis
1Dept of Medicine, University of Arkansas Center for Medical Sciences, Little Rock, USA.
Seminars in Respiratory Infections
|October 6, 1997
Summary
Blastomycosis treatment involves antifungal agents, with itraconazole often preferred over ketoconazole due to better efficacy and fewer side effects. Severe cases require amphotericin B.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Blastomycosis is a rare fungal infection prevalent in the midwestern and south-central United States.
- While some infections are subclinical, most diagnosed cases require antifungal treatment.
- Traditional treatments include amphotericin B, but its toxicity necessitates exploring oral alternatives.
Purpose of the Study:
- To review the efficacy and safety of various antifungal agents for blastomycosis.
- To compare the effectiveness of ketoconazole, itraconazole, and fluconazole.
- To provide guidance on selecting appropriate antifungal therapy based on disease severity.
Main Methods:
- Literature review of clinical studies and treatment guidelines for blastomycosis.
- Comparative analysis of antifungal drug efficacy and adverse effect profiles.
- Evaluation of treatment recommendations for mild, moderate, and severe blastomycosis.
Main Results:
- Ketoconazole is effective for non-overwhelming blastomycosis but has common adverse effects.
- Itraconazole demonstrates superior efficacy to ketoconazole, succeeding where ketoconazole fails or after relapse.
- Fluconazole is less effective, requiring higher doses compared to itraconazole.
Conclusions:
- Itraconazole is a preferred oral agent for blastomycosis due to its effectiveness and improved tolerability over ketoconazole.
- Amphotericin B remains the treatment of choice for life-threatening or central nervous system blastomycosis.
- Antifungal selection should be guided by disease severity and patient-specific factors.